RealPennies

Bristol-Myers Squibb Co. under the ticker symbol BMY. Here is some more information that we have about Bristol-Myers Squibb Co.

Get our alerts and future stock picks in your email inbox


What you feel with this company ? Are you willing to
11
2
2
Bristol-Myers Squibb Co.


Bristol-Myers Squibb Company (BMS) engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of pharmaceuticals and nutritional products worldwide. It operates in two segments, Pharmaceuticals and Nutritionals. The Pharmaceuticals segment offers cardiovascular products, including PLAVIX, AVAPRO/AVALIDE, and PRAVACHOL; virology products comprising REYATAZ, SUSTIVA, and BARACLUDE; oncology products comprising ERBITUX, TAXOL, SPRYCEL, and IXEMPRA; affective and other psychiatric disorder products, such as ABILIFY; immunoscience products comprising ORENCIA; and other pharmaceutical products that include EFFERALGAN, ASPIRINE UPSA, DAFALGAN, and FERVEX. It sells its pharmaceutical products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, and pharmacies. The Nutritionals segment manufactures, markets, distributes, and sells infant formulas and other nutritional products comprising ENFAMIL products that contain nutrients, such as docosahexaenoic and arachidonic acids. The company is also developing various compounds, which are in phase III clinical trials, including Apixaban, Saxagliptin, Dapagliflozin, Ipilimumab, Belatacept, XL-184, Tanespimycin, and Brivanib. In addition, it develops a therapeutic class of biologics called ADNECTINS. BMS has agreements with Sanofi-Aventis; Otsuka Pharmaceutical Co., Ltd.; ImClone Systems Incorporated; Gilead Sciences, Inc.; Medarex, Inc.; and AstraZeneca PLC, as well as collaborations with Pfizer Inc.; Exelixis, Inc.; and KineMed Inc. It also has an agreement with PDL BioPharma, Inc. for the development and commercialization of anti-CS1 antibody and elotuzumab for multiple myeloma; and a strategic alliance with Ensemble Discovery Corporation. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
25,000 Employees
Last Reported Date: 02/13/15
Founded in 1887
Last $60.92 USD
Change Today -0.54 / -0.88%
Volume 4.0M
As of 8:04 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

bristol-myers squibb co (BMY) Snapshot

Open
$61.24
Previous Close
$61.46
Day High
$61.55
Day Low
$60.87
52 Week High
01/12/15 - $64.44
52 Week Low
06/5/14 - $46.30
Market Cap
101.3B
Average Volume 10 Days
5.1M
EPS TTM
$1.30
Shares Outstanding
1.7B
EX-Date
12/30/14
P/E TM
46.7x
Dividend
$1.48
Dividend Yield
2.38%
Request Investor Kit
BMY:US Advanced Stock Chart

bristol-myers squibb co (BMY) Related Bloomberg News

AstraZeneca, Bristol-Myers Squibb: Intellectual Property
Bristol-Myers 2015 Sales Forecast Hit by Dollar’s Strength
Stronger Dollar Punishes U.S. Earnings From P&G to DuPont
Fed, U.S. GDP, Greece, Apple, Amazon: Week Ahead Jan. 24-31
Fed, U.S. GDP, Greek Vote, Apple, Amazon: Week Ahead Jan. 24-31

bristol-myers squibb co (BMY) Related News

Company News: Alstom, GE, American Apparel, Bristol-Myers Squibb, Airbus, Starbucks, Square
Prudential Piles on the Corporate Pensions
White-Collar Workers Live Longer and the Gap Is Widening
What's the Dollar Value of Online Patient Chatter?

bristol-myers squibb co (BMY) Key Developments

Bristol-Myers Squibb Company Receives FDA Acceptance for Biologics Licensing Application for Opdivo

Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the Biologics Licensing Application (BLA) for Opdivo(nivolumab)for the treatment of patients with advanced squamous non-small cell lung cancer (NSCLC) after prior therapy. The FDA also granted Priority Review for this application. The Prescription Drug User Fee Act (PDUFA) goal date for a decision is June 22, 2015. Bristol-Myers Squibb is leading research in an innovative field of cancer research and treatment known as immuno-oncology, which involves agents whose primary mechanism is to work directly with the body’s immune system to fight cancer. The company is exploring a variety of compounds and immunotherapeutic approaches for patients with different types of cancer, including researching the potential of combining immuno-oncology agents that target different and complementary pathways in the treatment of cancer.

Bristol-Myers Squibb Company Announces Encouraging Results from Phase III HIV-HCV Trial

Bristol-Myers Squibb Company (BMS) has announced results from ALLY-2, a Phase III clinical trial evaluating the investigational once-daily combination of daclatasvir and sofosbuvir for the treatment of patients with chronic hepatitis C virus, or HCV, coinfected with HIV. Among ALLY-2 patients treated for 12 weeks (treatment-naive and -experienced), 97% (n=149/153) achieved cure (sustained virologic response 12 weeks after treatment; SVR12). The study met the primary endpoint, with 96% (n=80/83) of treatment-naive genotype 1 patients achieving SVR12. Treatment with daclatasvir in combination with sofosbuvir in this study showed high SVR rates, with no discontinuations due to adverse events, and no serious adverse events related to study medications throughout the treatment phase. In ALLY-2, high SVR rates occurred among all patients treated for 12 weeks, regardless of prior treatment experience, HCV genotype, cirrhosis status, concurrent combination antiretroviral therapy regimen, or race. African-American patients comprised 34% of study participants; in this patient demographic, SVR12 rates were 98% (n=49/50). ALLY-2 also included an 8-week arm; 38 of 50 treatment-naive patients with HCV achieved SVR12. However, study investigators concluded that further studies are needed to assess the potential of shorter-duration, all-oral treatment regimens. Additional safety data demonstrated a low rate of Grade 3/4 lab abnormalities in the study: INR (1%), AST (0.5%), Tbili (4%), Lipase (3%). This Phase III open-label clinical trial randomized 151 treatment-naive and 52 treatment-experienced HCV (genotypes 1-4) patients coinfected with HIV-1 on a broad range of antiretroviral regimens, into 3 cohorts. Among treatment-naive patients, one cohort received daclatasvir 30, 60, or 90 mg (dose adjusted for concomitant antiretroviral therapy) plus sofosbuvir 400 mg once daily for 12 weeks, and another received the same dosage and combination for 8 weeks. The treatment-experienced cohort also received daclatasvir 30, 60, or 90 mg plus sofosbuvir 400 mg once daily for 12 weeks. Daclatasvir was dose-adjusted to accommodate concomitant antiretrovirals: 30 mg with ritonavir-boosted PIs, 90 mg with NNRTIs except rilpivirine. All cohorts had follow-up through post-treatment week 24. The primary endpoint was the SVR12 rate among genotype 1 treatment-naive patients after 12 weeks of treatment. Patients with cirrhosis were permitted.

Rigel Pharmaceuticals, Inc. and Bristol-Myers Squibb Announce Research and Development Collaboration for TGF Beta Receptor Kinase Inhibitors for Use in Immuno-Oncology Related Indications

Rigel Pharmaceuticals, Inc. and Bristol-Myers Squibb Company announced that they have entered into a collaboration agreement for the discovery, development and commercialization of cancer immunotherapies based on Rigel's extensive portfolio of small molecule TGF beta receptor kinase inhibitors. TGF beta can promote tumor growth, broadly suppress the immune system and increase the ability of tumors to spread in the body. The collaboration will focus on developing a new class of therapeutics aimed at increasing the immune system's activity against various cancers either as monotherapy or in combination with immune checkpoint inhibitors, including Bristol-Myers Squibb's Opdivo (nivolumab) and Yervoy (ipilimumab). Under the terms of the agreement, Bristol-Myers Squibb will obtain exclusive, worldwide rights to develop and commercialize small molecule therapeutics derived from Rigel's TGF beta library, including, but not limited to, those approved to treat cancer. Bristol-Myers Squibb will pay $30 million upfront and Rigel will be eligible to receive development and regulatory milestones that could total more than $309 million for a successful compound approved in multiple indications. Rigel will also be eligible to receive tiered royalties on the net sales of any products from the collaboration. Within the immune system, TGF beta often plays an immunosuppressive role by potently suppressing effector cell proliferation and function while simultaneously promoting differentiation of certain suppressive T-cells. This master regulator is often present within tumor microenvironments and can significantly dampen anti-tumor host immune responses. Current evidence suggests that TGF beta can arise from many sources, including the cancer itself, surrounding cells and infiltrating macrophages. Developing a drug that inhibits TGF beta signaling in cancer patients has the potential to counteract an important mechanism used by cancers to escape immuno-surveillance, thereby making this signaling pathway an appealing therapeutic target for immuno-oncology related applications.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BMY:US $60.92 USD -0.54

BMY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $60.50 USD -0.02
Amgen Inc $157.72 USD -1.25
Biogen Idec Inc $409.59 USD -0.51
Celgene Corp $121.53 USD -1.82
Novo Nordisk A/S kr319.70 DKK +3.70
 

Industry Analysis

BMY

Industry Average

Valuation BMY Industry Range
Price/Earnings 50.8x
Price/Sales 6.4x
Price/Book 6.8x
Price/Cash Flow 50.5x
TEV/Sales 5.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Cancer Drugs Boost Bristol-Myers Sales
  Read More...
Bristol-Myers Squibb
  Read More...
Bristol-Myers says strong dollar drags on 2015 outlook
  Read More...
Bristol-Myers issues cautious 2015 forecast due to strong dollar
  Read More...
Bristol-Myers
  Read More...
BRISTOL MYERS SQUIBB CO Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E
  Read More...
Bristol-Meyers beats fourth quarter expectations, but stock dips after dissappointing outlook
  Read More...
Bristol-Myers quarterly profit beats forecasts
  Read More...
Bristol-Myers beats Street 4Q forecasts
  Read More...
Bristol-Myers Squibb Appoints Giovanni Caforio, M.D., Chief Executive Officer, Effective May 5; Lamberto Andreotti to Become Chairman
[at noodls] - "This is an extraordinary company of talented people with incomparable passion and dedication to helping patients" NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced ...
  Read More...